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The connection between patents for pharmaceuticals and access to affordable medicines has 
elicited considerable attention and highly stimulating debates since the emergence of the 
World Trade Organisation (WTO) Agreement on Trade Related Aspects of Intellectual 
Property Rights (the TRIPS Agreement) as part of the Marrakesh Agreement Establishing 
WTO in 1994. The TRIPS Agreement is the first international convention to make it 
mandatory for all countries to make patents available in all fields of technology provided the 
invention to be patented meets the criteria for patentability. Consequently, countries like 
India, Brazil, China and Thailand that used to refuse to grant patents for pharmaceuticals 
were constrained to amend their patents laws to bring them in line with the WTO standard. 
Many developing countries did not even have legislation for a number of the intellectual 
property rights areas covered by the agreement at the time it was adopted.  The TRIPS 
Agreement has been criticised as being a significant part of the global access to medicines 
problem and strong arguments have been raised for having more flexible standards for the 
protection of patents particularly in relation to pharmaceuticals. 
 
This thesis examines the WTO regime for patent protection in the context of pharmaceuticals 
and the existing flexibilities in the TRIPS Agreement that countries seeking access to 
affordable patented pharmaceutical products might adopt. The effectiveness of the TRIPS 
compulsory licensing regime is examined, with particular focus on the limitations resulting 
from the TRIPS requirements for test data protection. The concepts of parallel importation 
and exhaustion of intellectual property (IP) rights are also examined with aview to 
ascertaining the extent to which they may serve as legal stratagems for developing countries 
seeking access to affordable medicines. The thesis argues that the existing frameworks for the 
right to health and the right to development in international law may provide a strong 
justification for the broad interpretation of the existing flexibilities in the TRIPS Agreement 
without the need for going through the very rigorous process of amending it.  
 
The thesis considers the patents and access to medicines problem in the context of the special 
and highly complex challenges people in Sub-Sahara Africa are currently encountering. It 
recommends the establishment of an African Free Trade Area to make it easier for Africa as a 
continent to make better use of the TRIPS flexibilities. The thesis argues that more than ever 
before, the time has come for Africa to harness her resources to address her access to 
v 
 
medicines problem through the use of all the available options in international economic law 
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